MicroRNA-761 Targets FGFR1 to Suppress the Malignancy of Osteosarcoma by Deactivating PI3K/Akt Pathway [Retraction]

Lv Z, Ma J, Wang J, Lu J. Onco Targets Ther. 2019;12:8501–8513. The Editor and Publisher of OncoTargets and Therapy wish to retract the published article. Concerns were raised over alleged image duplication in Figures 2C, 5C and 7A with similar images from unrelated articles, specifically: Figure 2C, panel HOS agomir-761 appears to have been duplicated with a similar image in Figure 5B from Wang et al, 2020 (https://doi.org/10.1016/j.prp.2020.152903). Figure 5C, panel HOS agomir-NC appears to have been duplicated with a similar image in Figure 5D from Chen et al, 2019 (https://doi.org/10.2147/OTT.S192137). Figure 5C, panel U2OS agomir-761+pCMV-FGFR1 appears to have been duplicated with a similar imges in Figure 2E from Ye et al, 2020 (https://doi.org/10.2147/CMAR.S228429). Figure 7A, appears to have been duplicated with similar images in Figure 7B from Song et al, 2018 (http://www.ajcr.us/files/ajcr0088433.pdf). The authors did not respond to our queries and the Editor determined the findings of the study were no longer valid and advised for the article to be retracted. Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction. The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”. This retraction relates to this paper